SYRE (Spyre Therapeutics) Retained Earnings: $-1,232.84 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRE Spyre Therapeutics Inc SYRE
26 GF Score
Price $102.30
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Retained Earnings?

Spyre Therapeutics SYRE -2.57% 26 Retained Earnings is $-1,232.84 Mil as of Jun. 2026. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Spyre Therapeutics's retained earnings for the quarter that ended in Jun. 2026 was $-1,232.84 Mil.

Spyre Therapeutics's quarterly retained earnings declined from Dec. 2025 ($-1,127.64 Mil) to Mar. 2026 ($-1,196.64 Mil) and declined from Mar. 2026 ($-1,196.64 Mil) to Jun. 2026 ($-1,232.84 Mil).

Spyre Therapeutics's annual retained earnings declined from Dec. 2023 ($-764.41 Mil) to Dec. 2024 ($-972.43 Mil) and declined from Dec. 2024 ($-972.43 Mil) to Dec. 2025 ($-1,127.64 Mil).


Spyre Therapeutics  (NAS:SYRE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Spyre Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Retained Earnings Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -341.81 -425.62 -764.41 -972.43 -1,127.64

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,053.92 -1,065.11 -1,127.64 -1,196.64 -1,232.84
SYRE
26GF Score
Spyre Therapeutics Inc SYRE
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-1,232.84 Mil mean?
Spyre Therapeutics (SYRE) has a Retained Earnings of $-1,232.84 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Retained Earnings too high?
Spyre Therapeutics' current Retained Earnings is $-1,232.84 Mil. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Retained Earnings compare to CRNX and PTGX?
Spyre Therapeutics' Retained Earnings of $-1,232.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Retained Earnings is $-1,232.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current Retained Earnings of $-1,232.84 Mil. The current Retained Earnings is $-1,232.84 Mil. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current Retained Earnings is $-1,232.84 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges 3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score

Get the complete analysis for SYRE

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$102.30
Price